SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-208137
Filing Date
2023-08-10
Accepted
2023-08-10 08:00:58
Documents
14
Period of Report
2023-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d538959d8k.htm   iXBRL 8-K 32627
2 EX-99.1 d538959dex991.htm EX-99.1 18043
6 GRAPHIC g538959g0810084359602.jpg GRAPHIC 3604
  Complete submission text file 0001193125-23-208137.txt   187834

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA grtx-20230809.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE grtx-20230809_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE grtx-20230809_pre.xml EX-101.PRE 11261
8 EXTRACTED XBRL INSTANCE DOCUMENT d538959d8k_htm.xml XML 3346
Mailing Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355
Business Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Filer) CIK: 0001563577 (see all company filings)

IRS No.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39114 | Film No.: 231157247
SIC: 2834 Pharmaceutical Preparations